Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.37 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.37 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552377 | 0.89 | LMNA (0.46) | L3MBTL1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL20551667 | 0.88 | CYP1A2 (0.46) | L3MBTL1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL20550873 | 0.87 | NPC1 (0.54) | L3MBTL1KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL22286177 | 0.85 | HTT (0.45) | L3MBTL1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL20552360 | 0.83 | LMNA (0.35) | L3MBTL1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL20551655 | 0.80 | LMNA (0.48) | L3MBTL1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL20551517 | 0.79 | ALDH1A1 (0.47) | L3MBTL1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL4625129 | 0.78 | KDM4E (0.47) | KDM4ELMNAKMT2AALDH1A1MAPT | |
| SCHEMBL20550832 | 0.78 | LMNA (0.47) | LMNAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20551307 | 0.78 | CYP1A2 (0.40) | L3MBTL1LMNAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | L3MBTL1 4638/4885KDM4E 4117/4885LMNA 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.